Microbix Biosystems (TSX:MBX) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


TSX:MBX Microbix Biosystems Inc TSX:MBX
52 GF Score
Price C$0.31
GF Value C$0.24
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Microbix Biosystems Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Microbix Biosystems's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

TSX:MBX vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Microbix Biosystems's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microbix Biosystems Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microbix Biosystems's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Microbix Biosystems's Margin of Safety % (DCF FCF Based) falls into.


TSX:MBX
52GF Score
Microbix Biosystems Inc TSX:MBX
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Microbix Biosystems (TSX:MBX) Overvalued in 2026?

Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued. The current stock price of C$0.31 is trading 27.1% above its estimated GF Value™ of C$0.24. GuruFocus considers Microbix Biosystems to be Modestly Overvalued.

Key valuation signals for TSX:MBX:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: C$0.24 vs. price of C$0.31 (27.1% above fair value)
  • GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the TSX:MBX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Microbix Biosystems Business Description

Other Exchanges MBXBF:USA
Address 265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
52GF Score

Get the complete analysis for TSX:MBX

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.31
Price
C$0.24
GF Value